NASDAQ:TCDA - Tricida Stock Price, Forecast & News

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida Inc (NASDAQ:TCDA) posted its quarterly earnings data on Thursday, November, 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.89). View Tricida's Earnings History.

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Tricida.

3 brokerages have issued 12-month price objectives for Tricida's stock. Their forecasts range from $48.00 to $58.00. On average, they anticipate Tricida's stock price to reach $51.50 in the next year. This suggests a possible upside of 42.7% from the stock's current price. View Analyst Price Targets for Tricida.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tricida.

News headlines about TCDA stock have been trending positive this week, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tricida earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Tricida.

Tricida saw a decrease in short interest in January. As of January 31st, there was short interest totalling 4,040,000 shares, a decrease of 7.6% from the January 15th total of 4,370,000 shares. Based on an average trading volume of 322,300 shares, the short-interest ratio is presently 12.5 days. Currently, 11.3% of the company's shares are short sold. View Tricida's Current Options Chain.

Some companies that are related to Tricida include ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Mirati Therapeutics (MRTX) and Nektar Therapeutics (NKTR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Global Blood Therapeutics (GBT), Galmed Pharmaceuticals (GLMD), GW Pharmaceuticals PLC- (GWPH), Ocular Therapeutix (OCUL), AT&T (T), Affimed (AFMD) and Arena Pharmaceuticals (ARNA).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (2.02%), State Street Corp (1.02%), Driehaus Capital Management LLC (0.53%), Candriam Luxembourg S.C.A. (0.37%), Charles Schwab Investment Management Inc. (0.31%) and Point72 Asset Management L.P. (0.30%). Company insiders that own Tricida stock include Beek Jeroen B Van, Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Steffen Pietzke and Wilhelm Stahl. View Institutional Ownership Trends for Tricida.

TCDA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Alpine Woods Capital Investors LLC, New York State Common Retirement Fund, ProShare Advisors LLC and Victory Capital Management Inc.. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl. View Insider Buying and Selling for Tricida.

TCDA stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Marshall Wace North America L.P., Bank of America Corp DE, Cubist Systematic Strategies LLC, Credit Suisse AG, Renaissance Technologies LLC, Barclays PLC and AQR Capital Management LLC. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $36.10.

Tricida has a market capitalization of $1.79 billion. The company earns $-102,810,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Tricida employs 76 workers across the globe.View Additional Information About Tricida.

The official website for Tricida is http://www.tricida.com/.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]